Mylan Price Target Increased to $38.00 by Analysts at JP Morgan Cazenove (MYL)

Share on StockTwits

JP Morgan Cazenove increased their price target on shares of Mylan (NASDAQ: MYL) from $34.00 to $38.00 in a research note issued on Wednesday, StockRatingsNetwork reports. The firm currently has an “overweight” rating on the stock. JP Morgan Cazenove’s target price indicates a potential upside of 27.13% from the stock’s previous close.

Several other analysts have also recently commented on the stock. Analysts at JPMorgan Chase reiterated an “overweight” rating on shares of Mylan in a research note to investors on Wednesday. They now have a $38.00 price target on the stock. Separately, analysts at Canaccord Genuity cut their price target on shares of Mylan to $32.00 in a research note to investors on Tuesday, April 2nd. They now have a “hold” rating on the stock. Finally, analysts at Sanford C. Bernstein downgraded shares of Mylan from an “outperform” rating to a “market perform” rating in a research note to investors on Monday, March 25th.

Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $34.00.

Mylan (NASDAQ: MYL) traded up 0.32% on Wednesday, hitting $29.987. Mylan has a 1-year low of $20.21 and a 1-year high of $31.22. The stock’s 50-day moving average is currently $29.44. The company has a market cap of $11.428 billion and a price-to-earnings ratio of 19.97.

Mylan, Inc. develops and markets generics along with a number of proprietary drugs. The Company’s product is for the treatment of migraine headaches, an orphan drug for the on/off fluctuation in people with Parkinson’s disease, and a wound care product to treat diabetic foot ulcers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Latest News

Allergen Bid Might Be Better for Teva
Allergen Bid Might Be Better for Teva
Biogen Slashes Forecast on Weakness of Tecfidera
Biogen Slashes Forecast on Weakness of Tecfidera
Whirlpool Profit for the Quarter Drops on Strong Dollar
Whirlpool Profit for the Quarter Drops on Strong Dollar
Morgan Stanley Revenue Helps It Beat the Street
Morgan Stanley Revenue Helps It Beat the Street
Hertz Projecting Earnings at Top of Forecasted Range
Hertz Projecting Earnings at Top of Forecasted Range
Earnings at Goldman Sachs Tumble
Earnings at Goldman Sachs Tumble


Advertisement
Advertisement
© 2006-2015 Ticker Report. Google+.